Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study).

Rigacci L, Battistini R, Kovalchuk S, Zoli V, Puccini B, Evangelista A, Arcaini L, Flenghi L, Visco C, Mian M, Di Rocco A, Peracchio C, Gotti M, Tisi MC, Palombi F, Pozzi S, Gioia D, Viero P, Martelli M.

Hematol Oncol 2022; 40: 609-616. doi: 10.1002/hon.3028. Epub 2022 Jun 5. PMID: 35612350 (IF 4.850)

https://www.ncbi.nlm.nih.gov/pubmed/